CIK 0002023658 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Bicara Therapeutics Inc.
Sign in to watch- Ticker
- BCAX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-468-4219
- Business address
- 116 HUNTINGTON AVENUE SUITE 703, BOSTON, MA, 02116
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $400,716
- in 1 filing, $401K under 10b5-1 plans
Net −$400,716. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-16 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +8,226 | $4.44 | $36K | 347,618 |
| 2026-04-16 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +7,454 | $3.79 | $28K | 355,072 |
| 2026-04-16 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +7,080 | $5.45 | $39K | 362,152 |
| 2026-04-16 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,226 | 56,684 | ||
| 2026-04-16 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,454 | 130,546 | ||
| 2026-04-16 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,080 | 558,432 | ||
| 2026-04-15 | Cohlhepp Ryan President and COO | Option exercise 10b5-1 | +8,000 | $3.79 | $30K | 208,641 |
| 2026-04-15 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −8,000 | $23.01 | $184K | 200,641 |
| 2026-04-15 | Cohlhepp Ryan President and COO | Sale 10b5-1 | −4,500 | $23.01 | $104K | 196,141 |
| 2026-04-15 | Cohlhepp Ryan President and COO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,000 | 109,334 | ||
| 2026-03-25 | Raben David Chief Medical Officer | Option exercise 10b5-1 | +5,500 | $3.79 | $21K | 60,786 |
| 2026-03-25 | Raben David Chief Medical Officer | Sale 10b5-1 | −5,500 | $18.95 | $104K | 55,286 |
| 2026-03-25 | Raben David Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,500 | 47,413 | ||
| 2026-03-23 | Hyep Ivan Chief Financial Officer | Option exercise 10b5-1 | +9,200 | $3.79 | $35K | 154,555 |
| 2026-03-23 | Hyep Ivan Chief Financial Officer | Sale 10b5-1 | −9,200 | $18.52 | $170K | 145,355 |
| 2026-03-23 | Hyep Ivan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,200 | 48,944 | ||
| 2026-03-20 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +1,596 | $3.79 | $6K | 340,988 |
| 2026-03-20 | Mazumdar Claire Chief Executive Officer | Sale 10b5-1 | −1,596 | $18.95 | $30K | 339,392 |
| 2026-03-20 | Mazumdar Claire Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,596 | 176,107 | ||
| 2026-03-19 | Mazumdar Claire Chief Executive Officer | Option exercise 10b5-1 | +6,905 | $3.79 | $26K | 346,297 |
Page 4 of 14 · 276 trades